Position in BNTX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$12,406,635
+$1,040,839 QoQ
Shares Held
133,333
+4.3% QoQ
Ownership
0.053%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
#58
of 282 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BNTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ARK Investment Management LLC holds $1,628,434,493 across 17 Biotechnology names. BNTX ranks #11 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CRSP |
CRISPR Therapeutics AG
|
9,460,939 | $515,999,613 | |
| 2 | BEAM |
Beam Therapeutics Inc.
|
10,234,862 | $351,260,463 | |
| 3 | NTLA |
Intellia Therapeutics, Inc.
|
16,875,684 | $285,536,573 | |
| 4 | RXRX |
Recursion Pharmaceuticals, Inc.
|
41,337,632 | $151,709,109 | |
| 5 | ABSI |
Absci Corp
|
12,925,271 | $149,803,890 | |
| 6 | NRIX |
Nurix Therapeutics, Inc.
|
1,793,196 | $43,502,934 | |
| 7 | PRME |
Prime Medicine, Inc.
|
8,348,746 | $30,806,872 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
300,770 | $23,848,053 |
All Filings in BNTX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $12,406,635 | 133,333 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $11,365,796 | 127,878 | Shares | Sole | 2026-05-12 | |
| No filing history on record for this holder in this stock. | ||||||